Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Future developments in immunotherapy for treatment of biliary tract cancer

Aiwu Ruth He • 5 Jul 2022
ESMO WCGIC 2022
Bile Duct Cancer Antibodies Durvalumab

Aiwu Ruth He, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA, comments on future avenues in research for the diagnosis and treatment of biliary tract cancer. Specifically, Dr He comments on the potential identification of novel biomarkers which may aid in the selection of patients with biliary tract cancer who could benefit from treatment with durvalumab plus chemotherapy. Moreover, personalized therapy and fibroblast growth factor receptor (FGFR) inhibitors for the treatment of biliary tract cancer are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Aiwu Ruth He

1:11
Highlights in biliary tract and liver cancers from ESMO WCGIC 2022
Aiwu Ruth He • 5 Jul 2022
5:45
Subgroup analysis of the TOPAZ-1 study by primary tumor location
Aiwu Ruth He • 5 Jul 2022

Related Videos

1:34
Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
Changhoon Yoo • 18 Jan 2024
0:33
Advancing precision medicine: exploring ctDNA analysis beyond rectal cancer
Changhoon Yoo • 3 Jun 2023
2:47
Sub-analysis of STAMP trial: ctDNA as predictive biomarker for CCA monitoring during ACT
Changhoon Yoo • 3 Jun 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
The content of VJOncology is intended for healthcare professionals